Morgan Stanley Assumes Halozyme Therapeutics (HALO) at Overweight

Morgan Stanley analyst Vikram Purohit assumes coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Overweight rating and a price target of $65.00 (from $53.00).

The analyst comments "We are assuming coverage of Halozyme with an Overweight rating and $65 PT. We believe HALO can continue to perform given the stock's defensive properties, continued commercial execution, and pipeline optionality."

For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.

Shares of Halozyme Therapeutics closed at $56.69 yesterday.

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Solar Industries (SOIL:IN) PT Raised to INR23,500 at ICICI Securities
• Stantec Inc. (STN:CN) (STN) PT Lowered to Cdn$169 at Desjardins